AXS Investments’s Editas Medicine EDIT Stock Holding History

AXS Investments’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,235	Closed	-$43.1K	–	397
2023 Q2	$43.1K	Hold	5,235	–	–	0.01%	354
2023 Q1	$38K	Buy	+5,235	New	+$46.5K	0.01%	315

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AXS Investments's EDIT Position: Q3 2023 in Review

AXS Investments sold out of Editas Medicine (EDIT) in Q3 2023, closing a stake of 5,235 shares — an estimated $43.1K sold.

AXS Investments first reported a position in EDIT in Q1 2023 and held it in 2 quarters. The position peaked at $43.1K in Q2 2023. 220 funds tracked by Wall St. Rank hold EDIT as of Q3 2023.

AXS Investments reported no remaining Editas Medicine position as of Q3 2023 after selling out during the quarter.
AXS Investments sold 5,235 Editas Medicine shares in Q3 2023, an estimated $43.1K.
AXS Investments first reported a position in Editas Medicine in Q1 2023 and held it in 2 quarters.
AXS Investments's Editas Medicine position peaked at $43.1K in Q2 2023.
220 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2023.

Based on AXS Investments's 13F filing for Q3 2023, filed 9 Nov 2023.